Myelodysplastic Syndrome Clinical Trial

ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Summary

The primary purpose of this study was to assess the noninferiority of ravulizumab compared to eculizumab in adult participants with PNH who had never been treated with a complement inhibitor (treatment-naïve).

View Full Description

Full Description

The study consisted of a 4-week screening period and a 26-week randomized treatment period (Primary Evaluation Period). After completion of the 26-week Primary Evaluation Period, all participants had the opportunity to enter the Extension Period, wherein participants will receive ravulizumab for up to 5 years.

View Eligibility Criteria

Eligibility Criteria

Criteria For Patient Cohort Originally Enrolled in ALXN1210-PNH-301 Study: Inclusion Criteria: 1. Male or female ≥18 years of age. 2. PNH diagnosis confirmed by documented by high-sensitivity flow cytometry. 3. Presence of 1 or more of the following PNH-related signs or symptoms within 3 months of screening: fatigue, hemoglobinuria, abdominal pain, shortness of breath (dyspnea), anemia (hemoglobin <10 gram/deciliter), history of a major adverse vascular event (including thrombosis), dysphagia, or erectile dysfunction; or history of packed red blood cells (pRBC) transfusion due to PNH. 4. Lactate dehydrogenase (LDH) level ≥1.5 times the upper limit of normal at screening. 5. Documented meningococcal vaccination not more than 3 years prior to, or at the time of, initiating study treatment. 6. Female participants of childbearing potential must use highly effective contraception starting at screening and continuing until at least 8 months after the last dose of ravulizumab. 7. Willing and able to give written informed consent and comply with study visit schedule. Exclusion Criteria: 1. Treatment with a complement inhibitor at any time. 2. History of bone marrow transplantation. 3. Body weight <40 kg. 4. Females who are pregnant, breastfeeding, or who have a positive pregnancy test at screening or Day 1. 5. Participation in another interventional clinical study or use of any experimental therapy within 30 days before initiation of study drug on Day 1 in this study or within 5 half-lives of that investigational product, whichever is greater. 6. History of or ongoing major cardiac, pulmonary, renal, endocrine, or hepatic disease that, in the opinion of the investigator or sponsor, would preclude participation. 7. Unstable medical conditions (for example, myocardial ischemia, active gastrointestinal bleed, severe congestive heart failure, anticipated need for major surgery within 6 months of randomization, coexisting chronic anemia unrelated to PNH). Eligibility Criteria For Roll-over Cohort: 1. All participants regardless of age, who are currently receiving ALXN1210 IV in an ongoing ALXN1210 study in patients with PNH 2. Participants must be willing and able to give written informed consent and to comply with all Extension study visits and procedures, including the use of any data collection device(s) to directly record patient data 3. Females of childbearing potential and male patients with female partners of childbearing potential must use highly effective contraception continuing until at least 8 months after the last dose of ravulizumab.

Study is for people with:

Myelodysplastic Syndrome

Phase:

Phase 3

Estimated Enrollment:

272

Study ID:

NCT02946463

Recruitment Status:

Completed

Sponsor:

Alexion Pharmaceuticals, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 112 Locations for this study

See Locations Near You

Research Site
Los Angeles California, 90033, United States
Research Site
Whittier California, 90603, United States
Research Site
Fort Worth Texas, 76104, United States
Research Site
Buenos Aires , C1015, Argentina
Research Site
Buenos Aires , C1425, Argentina
Research Site
Córdoba , X5004, Argentina
Research Site
Perth , 6000, Australia
Research Site
Linz , 4020, Austria
Research Site
Vienna , A-109, Austria
Research Site
Bruxelles , 1200, Belgium
Research Site
Hasselt , 3500, Belgium
Research Site
Leuven , 3000, Belgium
Research Site
Rio De Janeiro , , Brazil
Research Site
Salvador , 41253, Brazil
Research Site
Sao Paulo , 05403, Brazil
Research Site
Sao Paulo , , Brazil
Research Site
Edmonton Alberta, T6G 2, Canada
Research Site
Toronto Ontario, M4N 3, Canada
Research Site
Plzeň , 323 0, Czechia
Research Site
Prague , , Czechia
Research Site
Tallinn , 13419, Estonia
Research Site
Limoges , 87042, France
Research Site
MONTPELLIER Cedex 5 , 34295, France
Research Site
Paris Cedex 10 , 75475, France
Research Site
Pierre Benite , 69310, France
Research Site
Poitiers , 86021, France
Research Site
Rennes Cedex 9 , 35033, France
Research Site
Aachen , 52074, Germany
Research Site
Essen , 45122, Germany
Research Site
Ulm , 89081, Germany
Research Site
Ascoli Piceno , 63100, Italy
Research Site
Firenze , 50134, Italy
Research Site
Milano , 20122, Italy
Research Site
Napoli , 80131, Italy
Research Site
Vicenza , 36100, Italy
Research Site
Bunkyo-ku , 113-8, Japan
Research Site
Bunkyo-ku , 113-8, Japan
Research Site
Fukuoka-Shi , 812-8, Japan
Research Site
Fukushima-shi , 960-1, Japan
Research Site
Hamamatsu-shi , 432-8, Japan
Research Site
Kanazawa-shi , 920-8, Japan
Research Site
Kitakyusyu-shi , 806-8, Japan
Research Site
Koshigaya-shi , 343-8, Japan
Research Site
Kumamoto-shi , 860-8, Japan
Research Site
Nagoya-shi , 453-8, Japan
Research Site
Nishinomiya-shi , 663-8, Japan
Research Site
Ogaki-shi , 503-8, Japan
Research Site
Okayama-shi , 700-8, Japan
Research Site
Okayama-shi , 701-1, Japan
Research Site
Osakasayama-shi , 589-8, Japan
Research Site
Sapporo-shi , 060-8, Japan
Research Site
Shimotsuke-shi , 329-0, Japan
Research Site
Shinjuku-ku , 160-0, Japan
Research Site
Shinjuku-ku , 160-8, Japan
Research Site
Suita , 565-0, Japan
Research Site
Tokorozawa-shi , , Japan
Research Site
Tokyo , , Japan
Research Site
Toyoake-shi , 470-1, Japan
Research Site
Tsukuba-shi , 305-8, Japan
Research Site
Wakayama-shi , 641-8, Japan
Research Site
Daejeon , 35015, Korea, Republic of
Research Site
Goyang-si , 10408, Korea, Republic of
Research Site
Incheon , 21565, Korea, Republic of
Research Site
Jeonju-si , 561-7, Korea, Republic of
Research Site
JinJoo , 52727, Korea, Republic of
Research Site
Jung-gu , 41944, Korea, Republic of
Research Site
Seoul , 02841, Korea, Republic of
Research Site
Seoul , 03080, Korea, Republic of
Research Site
Seoul , 03722, Korea, Republic of
Research Site
Seoul , 04401, Korea, Republic of
Research Site
Seoul , 06591, Korea, Republic of
Research Site
Seoul , 07985, Korea, Republic of
Research Site
Seoul , 135-7, Korea, Republic of
Research Site
Seoul , 15270, Korea, Republic of
Research Site
Songpa-gu , 05505, Korea, Republic of
Research Site
Suwon-si , 16247, Korea, Republic of
Research Site
Ulsan , 44033, Korea, Republic of
Research Site
George , 10990, Malaysia
Research Site
Johor Bahru , 80100, Malaysia
Research Site
Kota Bharu , 15586, Malaysia
Research Site
Kota Bharu , 16150, Malaysia
Research Site
Kota Kinabalu , 88586, Malaysia
Research Site
Kuching , 93586, Malaysia
Research Site
Miri , 98000, Malaysia
Research Site
Sibu , 96000, Malaysia
Research Site
Monterrey , 64460, Mexico
Research Site
Gdańsk , 80-21, Poland
Research Site
Warszawa , 02-17, Poland
Research Site
Arkhangelsk , 16304, Russian Federation
Research Site
Barnaul , 65602, Russian Federation
Research Site
Irkutsk , 66407, Russian Federation
Research Site
Kirov , 61002, Russian Federation
Research Site
Moscow , 11799, Russian Federation
Research Site
Moscow , 12528, Russian Federation
Research Site
Murmansk , 18304, Russian Federation
Research Site
Novosibirsk , 63009, Russian Federation
Research Site
Omsk , 64401, Russian Federation
Research Site
Petrozavodsk , 18501, Russian Federation
Research Site
Rostov-on-Don , 34402, Russian Federation
Research Site
Saint-Petersburg , 19702, Russian Federation
Research Site
Saratov , 41002, Russian Federation
Research Site
St. Petersburg , , Russian Federation
Research Site
Ufa , 45000, Russian Federation
Research Site
Belgrade , 11000, Serbia
Research Site
Singapore , 11922, Singapore
Research Site
Madrid , 28040, Spain
Research Site
Majadahonda , 28220, Spain
Research Site
Uppsala , 75185, Sweden
Research Site
Changhua , 50006, Taiwan
Research Site
Hualien City , 97002, Taiwan
Research Site
Taichung , 404, Taiwan
Research Site
Tainan , 70403, Taiwan
Research Site
Taipei , 100, Taiwan
Research Site
Bangkok , 10330, Thailand
Research Site
Bangkok , 10700, Thailand
Research Site
Songkhla , 90110, Thailand
Research Site
Eskisehir , 26040, Turkey
Research Site
Airdrie , ML6 0, United Kingdom
Research Site
Leeds , , United Kingdom
Research Site
London , SE5 9, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Myelodysplastic Syndrome

Phase:

Phase 3

Estimated Enrollment:

272

Study ID:

NCT02946463

Recruitment Status:

Completed

Sponsor:


Alexion Pharmaceuticals, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.